

Brownstone-Lebwohl

Biologic Medication Quick Reference Sheet for Psoriasis and Atopic Dermatitis

Brand Name	Generic Name	Ages	Loading Dose	Maintenance Dose	Mechanism of Action
NEW Ebglyss (Atopic Dermatitis)	Lebrikizumab	12 yrs +	500 mg (two 250-mg injections) at wk 0 and 2, then 250 mg q2 wks until 16 wks or adequate response achieved	250 mg q4 wks	IL-13 antagonist
Enbrel*	Etanercept	PsA 18 yrs + PsO 4 yrs +	50 mg SQ Twice Weekly for 12 wks PEDS: 0.8 mg/kg q wk (max-dose 50 mg q wk)	50 mg SQ q wk	TNF-α blocker
Humira*	Adalimumab	PsO / PsA 18 yrs +	80 mg SQ on Day 1 and then 40 mg SQ on Day 8	40 mg SQ q2 wks	TNF-α blocker
Remicade*	Infliximab	PsO / PsA 18 yrs +	5 mg/kg IV wk 0, 2, and 6	5 mg/kg IV q8 wks	TNF-α blocker
Cimzia*	Certolizumab Pegol	PsO / PsA 18 yrs +	>90 kg: No Loading Dose ≤90 kg: 400 mg SQ at wk 0, 2 and 4	400 mg SQ q2 wks 200 mg SQ q2 wks	TNF-α blocker
Bimzelx*	Bimekizumab	PsO 18 yrs +	320 mg SQ at wk 0, 4, 8, 12, and 16	320 mg SQ q8 wks (for patients ≥ 120 kg, consider 320 mg q4 wks after wk 16)	IL-17A and F antagonist
Cosentyx*	Secukinumab	PsA 2 yrs + PsO 6 yrs +	300 mg SQ at wk 0, 1, 2, 3, and 4 PEDS: Dosage based on body weight and administered by SQ at wks 0, 1, 2, 3, and 4 and q4 wks Less than 50 kg = 75 mg Greater than or equal to 50 kg = 150 mg	300 mg SQ q4 wks	IL-17A antagonist
Taltz*	Ixekizumab	PsA 18 yrs + PsO 6 yrs +	160 mg at wk 0, then 80 mg at wk 2, 4, 6, 8, 10, and 12 PEDS: Greater than 50 kg = 160 mg at wk 0 then 80 mg q4 wks 25 to 50 kg = 80 mg at wk 0 then 40 mg q4 wks Less than 25 kg = 40 mg at wk 0 then 20 mg q4 wks	80 mg SQ q4 wks	IL-17A antagonist
Siliq	Brodalumab	PsO 18 yrs +	210 mg SQ at wk 0, 1, and 2	210 mg SQ q2 wks	IL-17A receptor antagonist
Stelara*	Ustekinumab	PsA 6 yrs + PsO 6 yrs +	≤100 kg: 45 mg SQ at wk 0 and 4 >100 kg: 90 mg SQ at wk 0 and 4 PEDS: Weight-based dosing recommended at initial dose, 4 weeks later, then q12 weeks. Less than 60 kg = 0.75 mg/kg 60 kg to 100 kg = 45 mg Greater than 100 kg = 90 mg	45 mg SQ q12 wks 90 mg SQ q12 wks	IL-12 and IL-23 antagonist
Tremfya*	Guselkumab	PsO / PsA 18 yrs +	100 mg SQ at wk 0 and 4	100 mg SQ q8 wks	IL-23 antagonist
Ilumya	Tildrakizumab	PsO 18 yrs +	100 mg SQ at wk 0 and 4	100 mg SQ q12 wks	IL-23 antagonist
Skyrizi*	Risankizumab	PsO / PsA 18 yrs +	150 mg SQ at wk 0 and 4	150 mg SQ q12 wks	IL-23 antagonist
Spevigo (GPP)	Spesolimab	12 yrs + (weighing at least 40 kg)	For treatment of flare: 900 mg IV Not experiencing a flare: 600 mg SQ	For treatment of flare: Repeat in one week if flare persists Not experiencing a flare: 300 mg SQ q4 weeks (SQ use after IV dose for flare treatment: Initiate or reinstitute at 300 mg SQ q4 weeks; no loading dose req'd)	IL-36 receptor antagonist
Dupixent (Atopic Dermatitis)	Dupilumab	6 mos +	600 mg SQ (Adult Dosing) PEDS 6m–5y: 5 to less than 15 kg = 200 mg SQ q4 wks 15 to less than 30 kg = 300 mg SQ q4 wks PEDS 6y–17y: 15 to less than 30 kg = 600 mg SQ then 300 mg q4 wks 30 to less than 60 kg = 400 mg SQ then 200 mg q2 wks 60 kg + = 600 mg SQ then 300 mg q2 wks	300 mg SQ q2 wk (Adult Dosing)	IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)
Adbry (Atopic Dermatitis)	Tralokinumab	12 yrs +	Adults: 600 mg (2 autoinjectors or 4 prefilled syringes) PEDS 12y-17y: 300 mg (2 prefilled syringes)	Adults: 300 mg q2 wks (1 autoinjector or 2 prefilled syringes); after 16 wks, q4 wks may be considered for adults <220 lbs who achieve clear or almost clear skin PEDS 12y-17y: 150 mg q2 wks (1 prefilled syringe)	IL-13 antagonist